Mitochondrial Myopathies in 2025: What Treatments Actually Work
A comprehensive review of pathophysiology, genetics, and emerging therapies for mitochondrial myopathies, spotlighting elamipretide and gene therapy.
Summary
Mitochondrial myopathies are rare genetic disorders caused by mutations in either mitochondrial or nuclear DNA that disrupt cellular energy production. They affect roughly 1 in 4,300 people and can involve muscle weakness, exercise intolerance, cardiac arrhythmias, neurological decline, and multi-organ dysfunction. Currently, no disease-modifying treatment exists. Management relies on vitamin and cofactor supplementation — such as CoQ10, riboflavin, and L-carnitine — though rigorous clinical evidence for these agents remains limited. The most promising emerging therapy is elamipretide, a mitochondria-targeting peptide with encouraging phase II data, while gene therapy approaches and mitochondrial replacement techniques represent longer-horizon experimental strategies. A multidisciplinary care team remains essential for optimizing patient quality of life.
Detailed Summary
Mitochondrial myopathies represent one of the most complex and heterogeneous categories of genetic disease, arising from dysfunction of the mitochondrial respiratory chain. The review by Bangeas et al. (2025) consolidates current understanding of pathophysiology, genetics, epidemiology, clinical presentation, and — most critically — the state of available and investigational treatments. Published in the International Journal of Molecular Sciences, this is a narrative review rather than a primary study, synthesizing existing literature to inform both clinical practice and future research directions.
The respiratory chain consists of five multiprotein complexes (I–V) embedded in the inner mitochondrial membrane. Genetic mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) can impair electron transport and oxidative phosphorylation, reducing ATP output and increasing reactive oxygen species (ROS). Key concepts such as heteroplasmy — the coexistence of mutant and wild-type mtDNA within a single cell — and the threshold effect (typically requiring 80–90% mutant mtDNA burden before clinical disease manifests) explain why identical mutations can produce dramatically different phenotypes across individuals and even within families. MtDNA is maternally inherited, while nDNA mutations follow Mendelian patterns (autosomal dominant, recessive, or X-linked).
Epidemiology data place prevalence at approximately 1 in 4,300 individuals, with carriers of pathogenic variants estimated at 1 in 200–250 people. The U.S. sees roughly 1,000–4,000 affected births annually. Classical clinical syndromes reviewed include MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged-red fibers), Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), Leigh syndrome, and NARP. Muscle biopsy findings such as ragged-red fibers on modified Gomori trichrome staining and COX-negative fibers forming a mosaic pattern are hallmark diagnostic findings, though biopsy can be normal in some patients.
On the treatment front, the review is candid that no disease-modifying therapy currently exists and that published management guidelines are largely expert-opinion based. The most widely used interventions are vitamin and cofactor supplementation: CoQ10 (ubiquinone or ubiquinol) is frequently prescribed for its role as an electron carrier and antioxidant, though clinical trial results have been inconsistent. Riboflavin (vitamin B2) has shown benefit particularly in patients with Complex I or Complex II deficiencies. L-carnitine is used to support fatty acid transport into mitochondria and reduce secondary metabolic stress. Idebenone, a synthetic CoQ10 analog, has demonstrated modest benefit in LHON — specifically for visual acuity preservation — and received orphan drug designation in Europe. Thiamine, vitamin E, and alpha-lipoic acid are also commonly included in 'mitochondrial cocktails,' though evidence for their isolated benefit is weak.
Elamipretide (SS-31, Bendavia) emerges as the most clinically promising agent reviewed. This tetrapeptide selectively targets cardiolipin in the inner mitochondrial membrane, stabilizing cristae architecture, reducing ROS production, and improving ATP synthesis. Phase II trials in Barth syndrome and primary mitochondrial myopathy demonstrated improvements in exercise tolerance (6-minute walk test distance), fatigue scores, and quality-of-life measures. Phase III trials are ongoing. Gene therapy approaches — including allotopic expression, mitochondria-targeted zinc-finger nucleases, and mitochondrial replacement therapy (three-parent IVF for maternal mtDNA mutation carriers) — are discussed as experimental but scientifically credible longer-horizon strategies. The review concludes that multidisciplinary care spanning neurology, cardiology, endocrinology, physiotherapy, and genetic counseling is essential, and calls urgently for larger, randomized controlled trials across all treatment modalities.
Key Findings
- No disease-modifying treatment currently exists for mitochondrial myopathies; all current guidelines are based on expert opinion rather than high-quality RCT evidence
- Mitochondrial diseases affect approximately 1 in 4,300 individuals, while pathogenic variant carriers may reach 1 in 200–250 people in the general population
- The threshold effect requires approximately 80–90% mutant mtDNA burden before clinical disease manifests, explaining the wide phenotypic variability within families
- Elamipretide (SS-31) showed improvements in 6-minute walk test distance and fatigue scores in Phase II trials for primary mitochondrial myopathy; Phase III trials are ongoing
- Idebenone demonstrated sufficient evidence for visual acuity benefit in LHON to receive European orphan drug designation, making it the closest to an approved targeted therapy
- Ragged-red fibers on modified Gomori trichrome staining and COX-negative mosaic fiber patterns on muscle biopsy remain key histological diagnostic markers, though biopsy can be normal
- Mitochondrial replacement therapy (three-parent IVF) is emerging as a preventive strategy for maternal mtDNA mutation carriers, with regulatory approval granted in the UK
Methodology
This is a narrative review article, not a primary experimental study — no original data, sample sizes, control groups, or statistical analyses were generated. The authors conducted a literature review of published research on mitochondrial myopathy pathophysiology, genetics, clinical syndromes, and management strategies. No systematic search protocol, PRISMA framework, or meta-analytic methods were described. The review draws on clinical trial data, case series, and expert consensus guidelines from existing literature.
Study Limitations
As a narrative review without a systematic search strategy, this article is subject to selection bias in the literature included and may not capture all relevant clinical trial data. The authors explicitly acknowledge that management recommendations are based on expert opinion due to the scarcity of large randomized controlled trials, limiting the strength of any clinical guidance. No conflicts of interest or external funding were declared, though the lack of a formal methodological framework (e.g., PRISMA) reduces the reproducibility of the review process.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.